Symbols

Silexion Therapeutics Corp (SLXN) Plunges 23.09% on Warrant Exercise

Generated by AI AgentAinvest Pre-Market Radar

Friday, Aug 1, 2025 9:08 am ET1min read

Aime Summary

- Silexion Therapeutics (SLXN) fell 23.09% pre-market after exercising warrants at $11.32/share to fund RNAi cancer therapy development.

- Preclinical data showing 97% pancreatic cancer cell inhibition previously drove shares to a $22.36 multi-year high.

- With $9.64M market cap, the biotech faces volatility risks as it balances capital-raising with therapeutic progress visibility.

On August 1, 2025, SilexionSLXN-- Therapeutics Corp (NASDAQ:SLXN) experienced a significant drop of 23.09% in pre-market trading, marking a notable shift in investor sentiment.

Silexion Therapeutics recently announced the exercise of new warrants, with an exercise price set at $11.32 per share. This move is part of the company's strategy to strengthen its financial position and support the development of its RNAi therapy for KRAS-driven cancers.

The company's stock has seen volatility due to the release of new preclinical data, which showed inhibition rates of up to 97% in pancreatic cancer cells. This positive data has contributed to a surge in the stock price, reaching a multi-year high of $22.36.

The market capitalization of Silexion Therapeutics stands at approximately $9.64 million, positioning it as a small-cap entity in the competitive biotech landscape.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue